Treating GERD: Lifestyle modifications vs medication
-
01/01/2025
Dear colleagues,
Gastroesophageal reflux disease (GERD) is a common reason for referral to gastroenterology. It affects a broad cross-section of our population and is often managed through a combination of lifestyle modifications and proton pump inhibitors (PPIs). However,
While PPIs are highly effective, concerns about their potential side effects frequently make headlines. Moreover, the financial burden of lifelong PPI use is a growing consideration. In this issue of Perspectives, Dr. Brijesh B. Patel and Dr. Juan D. Gomez Cifuentes explore these questions. Dr. Gomez Cifuentes highlights the benefits of lifestyle changes and identifies which strategies have proved most effective in his practice. Dr. Patel examines the ubiquitous use of PPIs and the challenges of sustaining adherence to lifestyle modifications. We hope these discussions will spark new ideas for managing GERD in your own practice.
We also welcome your thoughts on this topic — join the conversation on X at @AGA_GIHN.
Gyanprakash A. Ketwaroo, MD, MSc, is associate professor of medicine, Yale University, New Haven, and chief of endoscopy at West Haven VA Medical Center, both in Connecticut. He is an associate editor for GI & Hepatology News.
Do Lifestyle Changes Still Apply in the Treatment of GERD?
BY JUAN D. GOMEZ CIFUENTES, MD
Lifestyle changes are an essential part of managing gastroesophageal reflux disease (GERD). Increasingly, patients are asking about non-medication approaches to control their symptoms. These lifestyle modifications can be categorized into four main areas: 1) Weight loss, the cornerstone intervention, with significant symptom improvement observed after losing as little as 1.7 BMI points. 2) Dietary modifications, which includes both the traditional avoidance of trigger foods and the newer focus on a diet low in simple carbohydrates. 3) Bedtime adjustments, strategies that include elevating the head of the bed, sleeping on the left side, using anti-reflux pillows, and avoiding late-night meals. 4) Tobacco cessation, a key measure for reducing GERD symptoms and promoting overall health. I routinely discuss these changes with my patients, as they not only help manage GERD but also foster healthy habits and have a positive impact beyond the gastrointestinal tract.
Weight loss is the most impactful lifestyle intervention for GERD. Research shows a clear linear improvement in symptoms with weight reduction. Traditionally, losing 10% of body weight is a widely accepted goal, extrapolated from other obesity-associated conditions. A reduction in 3.5 points of BMI led to significant symptom improvement in landmark studies but also a modest reduction of 1.7 BMI points has been shown to provide symptom relief.1 Abdominal circumference is another key metric used to track progress, as central obesity rather than BMI alone is strongly linked with GERD. Goals are typically set at less than 40 inches for men and 35 inches for women. Patients using GLP-1 agonists should be informed that these medications may temporarily worsen GERD symptoms due to delayed gastric emptying, however in the long-term these symptoms are expected to improve once significant weight loss is achieved.
Food triggers vary among individuals, with common culprits including fatty meals, spicy foods, chocolate, tomato sauce, citrus fruits, and carbonated beverages. Patients tend to overemphasize diet elimination based on triggers and engage in strict diets. Patients are frequently afraid of these foods causing direct damage to the esophageal mucosa but the hypothesis is that these triggers worsen GERD by increasing transient relaxations of the lower esophageal sphincter. The evidence behind this and diet elimination based on triggers has always been weak. In my practice, I encourage patients to follow a diet low in simple carbohydrates. Simple carbohydrates are present in highly processed food, the average western diet contains ~140 g/day. In a trial, a diet low in simple sugars (monosaccharides and disaccharides < 62 g/day) without reducing total daily calories, objectively improved total acid exposure time in pH study.2
Thanks to gravity, nocturnal GERD symptoms are the culprit of many restless nights in these patients. I recommend avoiding food 3 hours before lying down. Since the stomach empties approximately 90% of its contents after 4 hours, waiting longer is not recommended and may result in hunger, making it harder to fall asleep. Sleeping on the left side, which takes advantage of the gastric anatomy, has proved to objectively decrease nocturnal acid exposure time, though some patients may find it challenging to maintain this position all night.3
Elevating the head of the bed is another effective intervention, but it must involve raising the upper body from the waist. Patients should avoid stacking ordinary pillows as this will only elevate the neck and place the body in an unnatural position for sleeping. The most effective strategies are putting blocks/bricks under the feet of the bed, using a bed wedge between the mattress and the box spring or using an adjustable bed frame. There are two types of pillows that have been shown to improve nocturnal GERD symptoms. The classic wedge pillows and the more expensive Medcline reflux relief system®. The Medcline pillow has a dual mechanism that elevates the upper body but also keeps the body on the left side position.4
Tobacco cessation is strongly recommended. Tobacco worsens GERD symptoms by reducing the lower esophageal sphincter pressure and decreasing saliva production which is one of the key components of the normal esophageal acid barrier. Moreover, it is a known risk factor for esophageal cancer. Alcohol has a variety of negative health impacts and decreasing alcohol intake is advised; however, the link between alcohol and GERD symptoms is less robust, especially in patients with low occasional consumption.
In summary, lifestyle modifications play a pivotal role in managing GERD symptoms, offering patients effective, non-pharmacologic strategies to complement medical treatments. Weight loss remains the cornerstone, with even modest reductions in BMI showing significant symptom relief. Dietary adjustments, particularly adopting a low-simple-carbohydrate diet, provide an evidence-based approach. Various bedtime interventions are available to improve nocturnal GERD symptoms. Finally, tobacco cessation is essential, not only for GERD symptom relief but also for overall health. By integrating these lifestyle changes into their routine, patients can improve GERD symptoms while building healthy habits.
Dr. Gomez Cifuentes is vice-chair in the section of gastroenterology at Presbyterian Healthcare Services, Albuquerque, New Mexico. He declares no conflicts of interest.
Medical Therapy Is the Cornerstone of Effective GERD Treatment
BY BRIJESH B. PATEL, MD
Today, I saw Mr. S in the office for gastroesophageal reflux disease (GERD). He has been on a trial of proton pump inhibitors (PPIs) and has implemented several lifestyle modifications to manage his reflux. He shared his frustrations, saying, “Doctor, I’ve tried changing my diet, sleeping in a recliner, and adjusting the timing of my meals. I’m practically not enjoying food anymore, and these lifestyle changes have affected my quality of life. Despite all this, I still wake up in the middle of the night with a ‘horrible taste’ in my mouth, and it’s ruining my sleep.”
Later that day, during a discussion with my trainees, one posed an important question: “What about lifestyle measures in the treatment of GERD?” This is a common query in both clinical and academic settings. GERD, with a prevalence estimated at ~20%, is often underreported as many patients begin self-medicating with over-the-counter acid suppressive therapies before seeking medical care. For gastroenterologists, PPIs, histamine-2 receptor antagonists (H2RAs), and now potassium-competitive acid blockers (PCABs) form the cornerstone of GERD management.
When I lecture medical students, residents, and fellows about GERD, I emphasize a standard approach: initiating an 8- to 12-week trial of PPIs followed by reassessment. I also stress the importance of combining medical therapy with lifestyle measures. However, the question remains: How adherent are our patients to these lifestyle changes? Similarly, how effectively are trainees integrating the value of lifestyle modifications into their practice? As an academic gastroenterologist, I can teach the theory, but is it being translated into real-world patient care?
The advent of PPIs has been a game changer for managing GERD symptoms and preventing disease progression. PPIs are the backbone of treatment in both gastroenterology and primary care, and they have profoundly improved patients’ quality of life. Most of my patients who present with GERD — whether due to uncontrolled reflux or acid exposure — have already been on a trial of PPIs before seeing me. My role often involves optimizing their timing of PPI administration, addressing incorrect usage, and reinforcing the importance of adherence. In some cases, I incorporate H2RAs as adjunctive therapy for patients who fail to respond adequately to PPIs, particularly when objective disease activity is confirmed through pH studies. These studies also highlight how challenging it is for many patients to maintain a refluxogenic-free lifestyle.
Lifestyle modifications should supplement and support GERD management. Regardless of medical specialty, lifestyle measures should be the first line of treatment. However, adherence and effectiveness vary widely. In reality, achieving sustained weight loss, meal timing adjustments, and dietary modifications (e.g., eliminating trigger foods like red wine, chocolate, coffee, and tomato-based sauces) is a significant challenge for patients. While these measures can reduce the need for PPIs in some cases, they are rarely sufficient as standalone treatments. Until lifestyle modifications are consistently and sustainably incorporated into daily routines, acid-suppressive therapy will remain the mainstay of GERD management.
Turning to newer therapies, PCABs are now FDA-approved for treating GERD. Early efficacy data suggest that PCABs are non-inferior to PPIs, with promising results in managing LA Class C and D esophagitis and maintaining symptom-free days. However, like PPIs, PCABs are associated with potential adverse effects, including C. difficile colitis, impacts on bone health, renal impairment, and mineral deficiencies. While these risks must be carefully discussed with patients, the benefits of medical therapy far outweigh the risks, especially for those with erosive esophagitis, Barrett’s esophagus, or a high-risk profile for esophageal cancer. In such cases, medical therapies provide superior disease control compared to lifestyle measures, supported by both subjective and objective data.
Managing GERD requires a multipronged approach. Relying solely on lifestyle measures rarely provides complete benefit, as restrictive dietary regimens are difficult to sustain long term. Like many, I can maintain a restrictive diet temporarily but find it unsustainable over time. Conversely, adherence to daily or twice-daily medications tends to be much higher than compliance with multi-level lifestyle changes (e.g., restrictive diets, weight loss, and trigger-food avoidance).
Our therapeutic arsenal for GERD continues to expand, enabling more effective management of patients with uncontrolled acid reflux. While I will continue to counsel patients and educate trainees on the value of lifestyle modifications, I emphasize the importance of adherence to timely medical therapy — whether with PPIs, H2RAs, or PCABs — as the cornerstone of effective GERD treatment.
Dr. Patel is associate program director in the division of digestive diseases & nutrition, at USF Health, Tampa, Fla. He declares no conflicts of interest.
Summary content
7 Key Takeaways
-
1
Developed a paper-based colorimetric sensor array for chemical threat detection.
-
2
Can detect 12 chemical agents, including industrial toxins.
-
3
Production cost is under 20 cents per chip.
-
4
Utilizes dye-loaded silica particles on self-adhesive paper.
-
5
Provides rapid, simultaneous identification through image analysis.
-
6
Inspired by the mammalian olfactory system for pattern recognition.
-
7
Future developments include a machine learning-enabled reader device.
The guidelines emphasize four-hour gastric emptying studies over two-hour testing. How do you see this affecting diagnostic workflows in practice?
Dr. Staller: Moving to a four-hour solid-meal scintigraphy will actually simplify decision-making. The two-hour reads miss a meaningful proportion of delayed emptying; standardizing on four hours reduces false negatives and the “maybe gastroparesis” purgatory that leads to repeat testing. Practically, it means closer coordination with nuclear medicine (longer slots, consistent standardized meal), updating order sets to default to a four-hour protocol, and educating front-line teams so patients arrive appropriately prepped. The payoff is fewer equivocal studies and more confident treatment plans.
Metoclopramide and erythromycin are the only agents conditionally recommended for initial therapy. How does this align with what is being currently prescribed?
Dr. Staller: This largely mirrors real-world practice. Metoclopramide remains the only FDA-approved prokinetic for gastroparesis, and short “pulsed” erythromycin courses are familiar to many of us—recognizing tachyphylaxis limits durability. Our recommendation is “conditional” because the underlying evidence is modest and patient responses are heterogeneous, but it formalizes what many clinicians already do: start with metoclopramide (lowest effective dose, limited duration, counsel on neurologic adverse effects) and reserve erythromycin for targeted use (exacerbations, bridging).
Several agents, including domperidone and prucalopride, received recommendations against first-line use. How will that influence discussions with patients who ask about these therapies?
Dr. Staller: Two points I share with patients: evidence and access/safety. For domperidone, the data quality is mixed, and US access is through an FDA IND mechanism; you’re committing patients to EKG monitoring and a non-trivial administrative lift. For prucalopride, the gastroparesis-specific evidence isn’t strong enough yet to justify first-line use. So, our stance is not “never,” it’s just “not first.” If someone fails or cannot tolerate initial therapy, we can revisit these options through shared decision-making, setting expectations about benefit, monitoring, and off-label use. The guideline language helps clinicians have a transparent, evidence-based conversation at the first visit.
The guidelines suggest reserving procedures like G-POEM and gastric electrical stimulation for refractory cases. In your practice, how do you decide when a patient is “refractory” to medical therapy?
Dr. Staller: I define “refractory” with three anchors.
1. Adequate trials of foundational care: dietary optimization and glycemic control; an antiemetic; and at least one prokinetic at appropriate dose/duration (with intolerance documented if stopped early).
2. Persistent, function-limiting symptoms: ongoing nausea/vomiting, weight loss, dehydration, ER visits/hospitalizations, or malnutrition despite the above—ideally tracked with a validated instrument (e.g., GCSI) plus nutritional metrics.
3. Objective correlation: delayed emptying on a standardized 4-hour solid-meal study that aligns with the clinical picture (and medications that slow emptying addressed).
At that point, referral to a center with procedural expertise for G-POEM or consideration of gastric electrical stimulation becomes appropriate, with multidisciplinary evaluation (GI, nutrition, psychology, and, when needed, surgery).
What role do you see dietary modification and glycemic control playing alongside pharmacologic therapy in light of these recommendations?
Dr. Staller: They’re the bedrock. A small-particle, lower-fat, calorie-dense diet—often leaning on nutrient-rich liquids—can meaningfully reduce symptom burden. Partnering with dietitians early pays dividends. For diabetes, tighter glycemic control can improve gastric emptying and symptoms; I explicitly review medications that can slow emptying (e.g., opioids; consider timing/necessity of GLP-1 receptor agonists) and encourage continuous glucose monitor-informed adjustments. Pharmacotherapy sits on top of those pillars; without them, medications will likely underperform.
The guideline notes “considerable unmet need” in gastroparesis treatment. Where do you think future therapies or research are most urgently needed?
Dr. Staller: I see three major areas.
1. Truly durable prokinetics: agents that improve emptying and symptoms over months, with better safety than legacy options (e.g., next-gen motilin/ghrelin agonists, better-studied 5-HT4 strategies).
2. Endotyping and biomarkers: we need to stop treating all gastroparesis as one disease. Clinical, physiologic, and microbiome/omic signatures that predict who benefits from which therapy (drug vs G-POEM vs GES) would transform care.
3. Patient-centered trials: larger, longer RCTs that prioritize validated symptom and quality-of-life outcomes, include nutritional endpoints, and reflect real-world medication confounders.
Our guideline intentionally highlights these gaps to hopefully catalyze better trials and smarter referral pathways.
Dr. Staller is with the Division of Gastroenterology, Massachusetts General Hospital and Harvard Medical School, Boston.

